中国植入物乳房重建临床实践现状:全国问卷调查结果
该调查由中国抗癌协会乳腺癌专业委员会等发起,向2017年乳腺癌手术量大于200例的110家医院发放问卷,了解植入物乳房重建(IBBR)开展现状。结果显示86.4%医院已开展IBBR,IBBR占所有乳房重建的65.75%,但仅占乳房全切除患者的7.06%,地区经济水平、医院手术量及对并发症和满意度的顾虑是主要影响因素。
要点
- IBBR已成为乳腺癌术后最常用的乳房重建方式,占所有重建的65.75%。
- IBBR在乳房全切除患者中占比仅7.06%,仍处于较低水平。
- 辅助放疗对假体的影响、术后并发症及患者满意度是主要顾虑。
核心结论
- 植入物乳房重建已成为乳腺癌手术后最常用的乳房重建方式,但其在乳房全切除患者中占比仍较低。
- 地区经济发展水平、医院手术量、专科医师培训及对并发症和患者满意度的顾虑是影响IBBR发展的主要因素。
研究设计与样本
- 由中国抗癌协会乳腺癌专业委员会及中国医师协会外科医师分会乳腺外科医师专业委员会发起的全国问卷调查。
- 调查对象为2017年乳腺癌手术量大于200例的110家医院。
- 调查内容包括IBBR应用现状、影响因素、选择原因及顾虑、应用时机及并发症。
- 统计分析采用χ²检验、Fisher确切概率法或Kruskal-Wallis秩和检验。
主要发现
- 86.4%(95/110)参与调查的医院已开展植入物乳房重建。
- 植入物乳房重建占所有乳房重建手术的65.75%(4 296/6 534)。
- 接受植入物乳房重建的乳房全切除患者比例为7.06%(4 296/60 877)。
- 各医院植入物乳房重建手术量为24(57.5)例[M(Q(R)),范围:2~565例]。
- IBBR开展比例与地区人均国内生产总值(H=10.47,P=0.005)及医院年手术量(H=8.30,P=0.016)有关。
关键数值与推荐
- 10.5%(10/95)的医院报告3~4级包囊挛缩发生率>10%。
- 4.2%(4/95)的医院报告需要外科干预的感染发生率为10%~20%。
- 1.1%(1/95)的医院报告扩张器或假体破裂发生率为6%~10%。
- 4.2%(4/95)的医院报告植入物取出或重建失败发生率为6%~15%。
- 选择IBBR的主要原因包括操作简单、学习曲线短及手术时间较短。
临床怎么用
- 临床选择IBBR时应综合评估辅助放疗对假体的影响、术后并发症风险及患者满意度。
- 开展IBBR需关注地区经济水平及医院手术量等现实因素对技术可及性的影响。
- 应加强专科医师培训以推动IBBR在乳房全切除患者中的规范应用。
局限性
- 调查仅纳入2017年乳腺癌手术量大于200例的110家医院,结果外推需谨慎。
- 并发症数据为医院层面报告的发生率区间,非患者个体水平精确统计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the current clinical practice of implant-based breast reconstruction (IBBR) in China. Methods: The current survey was sponsored by Chinese Anti-Cancer Association, Committee of Breast Cancer Society and Chinese Society of Breast Surgeons. A survey was mailed to 110 hospitals in China, which have more than 200 breast cancer operations performed in 2017. The survey mainly included questions on the clinical practice of IBBR, sociodemographic and geographical factors associated with IBBR practice, reasons and concerns for selecting IBBR, type and timing of breast reconstruction, and the complications of IBBR. Data were analyzed using χ(2) test, Fisher's exact test or Kruskal-Wallis rank sum test. Results: IBBR was available in 86.4% (95/110) included hospitals. It was predominantly performed breast reconstruction surgery, the proportion of IBBR in all the breast reconstruction was 65.75% (4 296/6 534). However, the rate of IBBR in all the patients received mastectomy was only 7.06% (4 296/60 877). Among all the included hospitals, the number of implant reconstructions performed in 2017 was 24 (57.5) cases (M(Q(R)), range: 2-565 cases). Factors associated with the performance of IBBR including regional per capita gross domestic product (H=10.47, P=0.005) and annual surgery volume (H=8.30, P=0.016). The main reasons for choosing IBBR were relatively simple surgical procedure, short learning curve and short operation time. The effects of adjuvant radiotherapy on prosthesis, postoperative complications and patient satisfaction were the main concerns for implant reconstruction. Compared with delay reconstruction, a higher proportion of IBBR was observed in immediate reconstruction (83.1% vs. 62.0%, χ(2)=12.522, P=0.000). In all, 10.5% (10/95) hospitals reported more than 10% grade Ⅲ to Ⅳ capsular contracture. The incidence of infections need surgical intervention was reported between 10% and 20% by 4.2% (4/95) hospitals. Hospitals with 6% to 10% implant rupture and 6% to 15% implant removal were 1.1% (1/95) and 4.2% (4/95) respectively. Conclusions: IBBR was the most common used surgery in breast reconstruction after mastectomy. However, the proportion of IBBR in patients after mastectomy was still low. Reginal economy, surgery volume of hospitals, lack of specialty training program and the concern about complications and patient's satisfaction were the factors affecting the development of IBBR. 目的: 了解我国植入物乳房重建的开展现状。 方法: 本研究由中国抗癌协会乳腺癌专业委员会及中国医师协会外科医师分会乳腺外科医师专业委员会发起,在全国范围内选择2017年乳腺癌手术量大于200例的110家医院进行问卷调查。调查项目包括植入物乳房重建的应用现状、影响应用的因素、选择的原因及顾虑、应用时机的选择及其并发症。采用χ(2)检验、Fisher确切概率法或Kruskal-Wallis秩和检验对数据进行分析。 结果: 参与调查的医院中,86.4%(95/110)已开展植入物乳房重建。植入物乳房重建占所有乳房重建手术的65.75%(4 296/6 534)。接受植入物乳房重建的乳房全切除患者的比例为7.06%(4 296/60 877),各医院植入物乳房重建手术量为24(57.5)例[M(Q(R)),范围:2~565例]。植入物乳房重建在乳房全切除术后患者中的开展比例与地区人均国内生产总值(H=10.47,P=0.005)、医院年手术量(H=8.30,P=0.016)有关。选择植入物乳房重建的主要原因为操作简单、学习曲线短及手术时间较短。辅助放疗对假体的影响、术后并发症及患者满意度是选择植入物乳房重建的主要顾虑。相较于延期乳房重建,植入物乳房重建在即刻乳房重建中占比更高(83.2%比60.0%,χ(2)=12.522,P=0.000)。植入物相关严重并发症发生率方面,10.5%(10/95)的医院3~4级包囊挛缩发生率>10%,4.2%(4/95)的医院需要外科干预的感染发生率为10%~20%,扩张器或假体破裂发生率为6%~10%、植入物取出或重建失败发生率为6%~15%的医院分别为1.1%(1/95)和4.2%(4/95)。 结论: 植入物乳房重建已成为乳腺癌手术后最常用的乳房重建方式。然而其在乳房全切除术患者中占比仍较低。地区经济发展水平、医院手术量、专科医师的培训及对植入物乳房重建并发症和患者满意度的顾虑是影响其发展的主要因素。.
引用
- Guo R, Xiu BQ, Su YH, et al. [Current practice of implant-based breast reconstruction: results from China national practice questionnaire survey]. Zhonghua Wai Ke Za Zhi. 2019. PMID: 31422632. doi:10.3760/cma.j.issn.0529-5815.2019.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。